Indegene hits new high

Indegene is among the top gainers on the BSE today, rising 4.39% to Rs. 619.50. The stock opened at Rs. 595.05 against the previous close of Rs. 593.45 and touched a fresh 52-week high of Rs. 621.15. Trading activity was modest, with 0.64 lakh shares traded and turnover at Rs. 3.90 crore. The company’s market cap stood at Rs. 14,927.89 crore.

Trigger

• Stock touched a fresh 52-week high amid renewed interest in healthcare-tech and life-sciences outsourcing.
• Market sentiment has improved around companies providing digital, AI and commercialisation services to global pharma clients.
• Many brokerage houses have initiated coverage
• Indegene’s strategic collaboration with Microsoft for Generative AI adoption in life sciences remains a key long-term narrative.
• The company has also launched Cortex, a GenAI platform built specifically for the life-sciences industry.
• Q1 FY27 revenue stood at Rs. 1,063.10 crore, up 5.95% QoQ, while operating profit rose 21.56% QoQ to Rs. 174.20 crore.

The market is looking at Indegene as a specialised healthcare-tech outsourcing play rather than a plain IT services company. Its business sits inside pharma workflows , medical content, regulatory support, commercial operations, data, analytics and AI-led productivity tools. This gives it a sharper positioning at a time when global pharma companies are trying to cut costs, speed up drug launches and outsource more non-core work.

The AI angle is also helping sentiment. Indegene is not a frontier AI company, but it is trying to apply GenAI to real pharma use-cases such as medical-regulatory review, content creation, commercial operations and life-sciences workflows. That makes the story more credible than a generic “AI theme” rally, because the use-case is vertical-specific.

That said, the brokerage-led excitement should be treated with caution. When a stock is already near a 52-week high and fresh positive coverage comes in, it can also create a profit-booking window for earlier investors. The valuation is no longer cheap, with the stock trading at around 37x consolidated PE and 66x standalone PE.